Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

1248P - Development of a high performance and noninvasive diagnostic model using blood cell-free microRNAs for multi-cancer early detection


21 Oct 2023


Poster session 14


Laboratory Diagnostics;  Clinical Research;  Translational Research

Tumour Site


Jason Zhang


Annals of Oncology (2023) 34 (suppl_2): S711-S731. 10.1016/S0923-7534(23)01942-7


J. Zhang1, H. Hu2

Author affiliations

  • 1 Sophomore, Del Norte High School, 92127 - San Diego/US
  • 2 Bioinformatics, Chan Soon-Shiong Institute of Molecular Medicine at Windber, 15963 - Windber/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1248P


Despite recent progress, developing a low-cost and high-accuracy test for multi-cancer early detection (MCED) remains a challenge worldwide. Here, we report the development of a diagnostic model for MCED based on blood cell-free microRNAs (miRNA) using a training set composed of multiple cancer types.


We have previously assembled 3 large serum microarray datasets that assessed the expression of 2588 serum miRNAs from 6283 cancer patients (pts) across 13 cancer types and 5130 non-cancer controls, and developed a 4-miRNA model for MCED from a lung cancer training set ( Cancers 2022 ,14:1450). In the current study, an expanded training set including 1408 pts from 7 cancer types and 1408 age-, gender-matched non-cancer controls was compiled with the remaining participants organized into 3 validation sets. A new diagnostic model was built from the expanded training set by Linear Model for Microarray Data (limma) and 10-fold cross-validation.


A new 4-miRNA diagnostic model was developed from the training set. In validation set 1 including 1358 lung cancer pts and 1501 non-cancer controls, the model achieved 99% sensitivity and 100% specificity. In validation set 2 comprising 1438 pts across 12 cancer types and 1623 non-cancer controls, the model achieved > 90% sensitivity for 8 cancer types and at least 75% sensitivity for 3 cancer types along with 99% specificity. In validation set 3 comprising 2079 pts across 4 cancer types and 598 non-cancer controls, the model achieved >90% sensitivity for all 4 cancer types and 98% specificity. Overall, the new model showed improved performance compared to the old model (p<0.001). Table: 1248P

Cancer type N Sensitivity of new model Sensitivity of old model
Validation set 2
Biliary Tract 40 100% 98%
Bladder 192 99% 98%
Breast 135 1% 0%
Colorectal 155 92% 86%
Esophageal 124 91% 85%
Gastric 150 100% 100%
Glioma 40 98% 88%
Liver 148 84% 84%
Ovarian 133 79% 62%
Pancreatic 149 91% 83%
Prostate 40 98% 92%
Sarcoma 132 75% 72%
Validation set 3
Gastric 1067 100% 100%
Glioma 196 96% 87%
Esophageal 247 92% 85%
Prostate 569 95% 90%


Our study provided further evidence in demonstrating that circulating miRNA-based diagnostic models have the potential to be developed into inexpensive, highly accurate and noninvasive tests for MCED. Models trained using multiple cancer types outperformed those trained from a single cancer type.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


H. Hu: Financial Interests, Personal, Stocks or ownership: miRoncol Diagnostics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.